AExcellent

Boston Scientific Corporation(BSX)

A

Financial data as of Dec 31, 2024Improving · Healthcare

FCF Margin14.1%Free Cash Flow / Revenue
Cash Conversion185.3%Operating CF / Net Income
Free Cash Flow$2.4B
Revenue$16.7B
Net Cash-$10.7BNet debt position
Debt / FCF4.7xElevated debt burden
Current Ratio1.08Adequate short-term liquidity
YoY FCF Growth+56.4%5 of 5 quarters positive

How This Grade Was Calculated

Base grade from FCF margin, adjusted by financial health factors

BaseB
+0.5Healthy FCF margin with manageable debt (14.1%, 4.7x)
+1Strong YoY FCF growth (56.4% YoY)
FinalA

Analysis Summary

Strengths

  • Healthy FCF margin (14.1%)
  • Excellent cash conversion (185%)
  • Strong YoY FCF growth (+56.4%)
  • FCF trend is improving

Concerns

  • Net debt position ($10.7B)

Financial Breakdown

Key financials compared side by side

Margin Composition

FCF Margin14.1%
Net Margin11.1%
Operating CF Margin20.5%
CapEx Ratio6.4%

Balance Sheet Health

Debt, liquidity, and leverage snapshot

Net Cash-$10.7BNet debt position
Debt / FCF4.7xElevated debt burden
Current Ratio1.08Adequate liquidity
Debt / Equity0.51Low leverage

Quarterly FCF Trend

+56.4% YoYImproving (+56.4%)

Free cash flow per quarter

Sector Comparison — Healthcare

FCF Margin ranked against sector peers

View all →

Detailed Metrics

Company NameBoston Scientific Corporation
SectorHealthcare
Free Cash Flow$2.4B
Revenue$16.7B
Net Income$1.9B
Operating Cash Flow$3.4B
Capital Expenditure$1.1B
FCF Margin14.1%
Cash Conversion Rate185.3%
Net Margin11.1%
Total Debt$11.1B
Total Cash$414.0M
Net Cash-$10.7B
Current Ratio1.08
Debt / Equity0.51
Debt / FCF4.7x
YoY FCF Growth+56.4%
Positive Quarters5 of 5
Trend DirectionImproving
Report DateDec 31, 2024
GradeA
Data SourceYahoo Finance